IP Library Patent Application 16658195
Patent Application
App. No. 16/658,195

SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/658,195
Abstract

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Claims (14)

1 .- 20 . (canceled)

21 . A method comprising:

(a) obtaining a sample comprising a nucleic acid sequence, wherein said nucleic acid sequence comprises a 5-hydroxymethylcytosine and a 5-methylcytosine;

(b) performing a sequencing; and

(c) distinguishing said 5-hydroxymethylcytosine from said 5-methylcytosine.

24 . The method of claim 1 , wherein said nucleic acid sequence is a mammalian nucleic acid sequence.

25 . The method of claim 1 , wherein said sample comprises genomic DNA.

26 . The method of claim 1 , wherein said sample comprises an extracellular fluid.

27 . The method of claim 1 , wherein said sequencing is high-throughput sequencing.

28 . The method of claim 1 , wherein said sample is from a subject having or suspected of having cancer.

29 . The method of claim 1 , wherein said distinguishing comprises detecting said 5-hydroxymethylcytosine.

30 . The method of claim 1 , wherein said distinguishing comprises detecting said 5-methylcytosine.

31 . The method of claim 1 , further comprising contacting said nucleic acid sequence with a dioxygenase or catalytically active fragment thereof to convert a methylated cytosine in said nucleic acid sequence to a modified base, wherein said dioxygenase or said catalytically active fragment thereof comprises TET1, TET2, TET3, CXXC4, a catalytically active fragment of any of these, or any combination thereof.

32 . The method of claim 31 , further comprising contacting said nucleic acid sequence with sodium bisulfite.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: RAO, ANJANA; TAHILIANI, MAMTA; KOH, KIAN PENG
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 053266/0148 →
MERGER Recorded Jul 21, 2020
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 053266/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 053266/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: AGARWAL, SUNEET
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 053266/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: IYER, ARAVIND
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 053266/0191 →